SHERWIN STEPHEN A

Track

Insider profile

Performance

Overall performance
3.1
Performance over holding periods
3.1
30 days 90 days 120 days
Average return 21% 8.2% 15.1%
Success rate 100% 68% 82%
Transactions
1 0% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance
SHERWIN STEPHEN A's trades of Neurocrine Biosciences Inc's stock


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2026-06-09 2026-06-05
PlS Planned sale
36,571 +2.8%
57.76
US$4,045,073 		36,571 +2.8% 57.76 US$4,045,073
2026-06-09 2026-06-05
PlS Planned sale
12,288 +46.5%
166.42
US$4,637,330 		12,288 +46.5% 166.42 US$4,637,330
2026-06-09 2026-06-05
PlS Planned sale
7,160 +16.6%
11.90
US$86,384 		7,160 +16.6% 11.90 US$86,384
2026-06-09 2026-06-05
PlS Planned sale
2,549 -7.7%
164.44
US$419,156 		2,549 -7.7% 164.44 US$419,156
2026-06-09 2026-06-05
PlS Planned sale
7,883 -19.3%
163.81
US$1,291,291 		7,883 -19.3% 163.81 US$1,291,291
2026-06-05 2026-06-05
PrS Proposed sale
25,000
167.35
US$4,183,750 		25,000 167.35 US$4,183,750
2026-06-05 2026-06-05
PrS Proposed sale
25,000
167.35
US$4,183,750 		25,000 167.35 US$4,183,750
2025-03-10 2025-03-07
US Biogen Inc (BIIB)
S Sale
8,760 -43.6%
150.02
US$1,314,142 		8,760 -43.6% 150.02 US$1,314,142
2025-03-07 2025-03-07
US Biogen Inc (BIIB)
PrS Proposed sale
8,760
147.37
US$1,290,961 		8,760 147.37 US$1,290,961
2025-02-14 2025-02-13
PlS Planned sale
13,831 -56.4%
116.69
US$1,613,923 		13,831 -56.4% 116.69 US$1,613,923
2025-02-13 2025-02-13
PrS Proposed sale
13,831
117.18
US$1,620,717 		13,831 117.18 US$1,620,717
2024-05-30 2024-05-29
PlS Planned sale
15,000 -36.1%
133.47
US$2,002,010 		15,000 -36.1% 133.47 US$2,002,010
2024-05-30 2024-05-29
PlS Planned sale
25,000 -48.5%
133.46
US$3,336,555 		25,000 -48.5% 133.46 US$3,336,555
2024-05-29 2024-05-29
PrS Proposed sale
40,000
133.46
US$5,338,563 		40,000 133.46 US$5,338,563
2023-01-05 2023-01-03
PlS Planned sale
15,000 -37.4%
118.85
US$1,782,752 		15,000 -37.4% 118.85 US$1,782,752
2023-01-05 2023-01-03
PlS Planned sale
15,000 -37.4%
118.87
US$1,782,976 		15,000 -37.4% 118.87 US$1,782,976
2022-01-26 2022-01-24
PlS Planned sale
15,000 -37.4%
74.43
US$1,116,378 		15,000 -37.4% 74.43 US$1,116,378
2020-04-30 2020-04-28
PlS Planned sale
17,687 -37.2%
99.39
US$1,757,966 		17,687 -37.2% 99.39 US$1,757,966
2020-03-12 2020-03-11
US Biogen Inc (BIIB)
PlS Planned sale
270 -1.7%
295.29
US$79,728 		270 -1.7% 295.29 US$79,728
2020-03-12 2020-03-11
US Biogen Inc (BIIB)
PlS Planned sale
2,164 -13.1%
295.22
US$638,845 		2,164 -13.1% 295.22 US$638,845
2013-05-28 2013-05-23
B Purchase
7,003 +inf%
0.01
US$70 		7,003 +inf% 0.01 US$70